LON:CIR - Circassia Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started GBX 38 +0.10 (+0.26 %) (As of 02/19/2019 04:00 PM ET)Previous CloseGBX 37.90Today's RangeGBX 36 - GBX 38.5052-Week RangeN/AVolume1.50 million shsAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/ABetaN/A ProfileDiscussionAnalyst RatingsChartInsider TradesHeadlinesOptions Chain Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Circassia Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of products for the treatment of respiratory diseases. The company markets NIOX and NIOX VERO for use in asthma diagnosis and management; and Tudorza for the treatment of chronic obstructive pulmonary disease (COPD). Its pipeline products include Flixotide, Seretide, and Flovent for asthma; and various novel specialty for COPD treatments, such as Duaklir, Spiriva, Novel LABA/LAMA formulation, and novel COPD therapy formulation. The company has a collaboration agreement with AstraZeneca to promote Tudorza and for COPD treatment, and has the United States commercial rights to COPD therapy Duaklir. It markets its products directly to specialists in the United States, the United Kingdom, and Germany, as well as through a network of partners in China, Japan, Europe, and internationally. Circassia Pharmaceuticals plc was founded in 2006 and is headquartered in Oxford, the United Kingdom. Receive CIR News and Ratings via Email Sign-up to receive the latest news and ratings for CIR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange LON Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolLON:CIR Previous Symbol CUSIPN/A Webwww.circassia.co.uk Phone44 1865 405 560Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding SharesN/AMarket CapN/A OptionableOptionable Circassia Pharmaceuticals (LON:CIR) Frequently Asked Questions What is Circassia Pharmaceuticals' stock symbol? Circassia Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "CIR." What price target have analysts set for CIR? 3 equities research analysts have issued twelve-month target prices for Circassia Pharmaceuticals' stock. Their predictions range from GBX 65 to GBX 140. On average, they expect Circassia Pharmaceuticals' share price to reach GBX 106.25 in the next twelve months. This suggests a possible upside of 179.6% from the stock's current price. View Analyst Price Targets for Circassia Pharmaceuticals. What is the consensus analysts' recommendation for Circassia Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Circassia Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Circassia Pharmaceuticals. Has Circassia Pharmaceuticals been receiving favorable news coverage? News coverage about CIR stock has trended somewhat positive on Tuesday, InfoTrie reports. The research firm ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Circassia Pharmaceuticals earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next several days. Who are some of Circassia Pharmaceuticals' key competitors? Some companies that are related to Circassia Pharmaceuticals include 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Almirall (LBTSF), AorTech International (AOR), Arix Bioscience (ARIX), Arno Therapeutics (ARNI), Axim Biotechnologies (AXIM), Axovant Sciences (AXGT), Biocure Technology (CURE), Biotest (BIO) and Bioventix (BVXP). Who are Circassia Pharmaceuticals' key executives? Circassia Pharmaceuticals' management team includes the folowing people: Mr. Steven Charles Andrew Harris, Co-Founder, CEO & Director (Age 52)Mr. Julien Cotta, CFO, Company Sec. & Director (Age 55)Dr. Roderick Peter Hafner, Sr. VP of R&D and Director (Age 53)Ms. Nina Kataria, Sr. VP Global HRDr. Kathleen Rickard, Head of Clinical Devel. (Age 61) How do I buy shares of Circassia Pharmaceuticals? Shares of CIR and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Circassia Pharmaceuticals' stock price today? One share of CIR stock can currently be purchased for approximately GBX 38. What is Circassia Pharmaceuticals' official website? The official website for Circassia Pharmaceuticals is http://www.circassia.co.uk. How can I contact Circassia Pharmaceuticals? The company can be reached via phone at 44 1865 405 560. MarketBeat Community Rating for Circassia Pharmaceuticals (LON CIR)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 31 (Vote Outperform)Underperform Votes: 31 (Vote Underperform)Total Votes: 62MarketBeat's community ratings are surveys of what our community members think about Circassia Pharmaceuticals and other stocks. Vote "Outperform" if you believe CIR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CIR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/19/2019 by MarketBeat.com StaffFeatured Article: What is the LIBOR?